Shuttle Pharmaceuticals Holdings Inc. (SHPH)
SHPH trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | SHPH on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001757499 |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements contained in this report are issued." | 10-Q 2026-09-24 |
| Cash and burn | $90K cash; operating cash flow -$1.6M a quarter. | Report 2026-06-30 |
| Shares outstanding | 4,764,696 (2026-09-21); 1,070,773 a year earlier; 15,733,165 three years earlier. 1y figure adjusted for splits (1-for-10 overall); 3y figure adjusted for splits (1-for-2000 overall). | Cover page 2026-09-21 |
| Reverse splits, 3 years | 3; latest 1-for-10 on 2026-06-11 | Source 2026-06-11 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-08-28 |
| Auditor | Forvis Mazars, LLP, Atlanta, Georgia, United States; changed auditors 2 times in 24 months | 8-K 4.01 2026-11-06 |
| Late filings, 12 months | 1 NT notice | NT 10-Q 2026-08-17 |
| Insider trades, 12 months | Bought $182K, sold $505K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$3.1M | -$568K | $90K | No debt tags | Needs four quarters | 10-Q 2026-09-24 |
| Q1 2026 2026-03-31 | Not filed | -$2.2M | -$2.4M | $1.1M | No debt tags | Needs four quarters | 10-Q 2026-09-24 |
| Q4 2025 2025-12-31 | Not filed | -$2.6M | -$973K | $334K | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$2.3M | -$2.6M | $2.1M | No debt tags | Needs four quarters | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | Not filed | -$3.7M | -$3.4M | $4.8M | $10.0M | Needs four quarters | 10-Q 2026-09-24 |
| Q1 2025 2025-03-31 | Not filed | -$3.1M | -$2.5M | $4.5M | $10.0M | Needs four quarters | 10-Q 2026-09-24 |
| Q4 2024 2024-12-31 | Not filed | -$1.6M | -$2.7M | $1.9M | $10.2M | Needs four quarters | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | Not filed | -$3.8M | -$2.0M | $157K | $10.0M | Needs four quarters | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | -18.9% |
| 1 month | -12.5% |
| 3 months | -1.1% |
| Year to date | -74.8% |
| 1 year | -80.4% |
| From 52-week high | -81.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CELU | Celularity Inc. | $0.6191 | -1.75% | $20.1M |
| IGC | IGC Pharma Inc. | $0.1750 | -0.57% | $20.4M |
| AYTU | Aytu BioPharma Inc. | $1.82 | +1.68% | $19.8M |
| CPHI | China Pharma Holdings Inc. | $0.4800 | -7.35% | $20.7M |
| TXMD | TherapeuticsMD Inc. | $1.81 | -3.21% | $20.9M |
| ATOS | Atossa Therapeutics Inc. | $1.93 | -1.53% | $19.3M |
| COCP | Cocrystal Pharma Inc. | $0.9777 | -0.24% | $18.8M |
| LPCN | Lipocine Inc. | $1.66 | -2.92% | $18.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier